Interestingly, an analysis of The Cancer Genome Atlas datasets revealed that higher GUCY1B1 expression is significantly associated with reduced overall survival in patients diagnosed with uveal melanoma, colorectal carcinoma, and mesothelioma (Appendix Fig. S11A), further substantiate the notion that suppressing sGC signaling holds therapeutic benefits. This evidence concerns the gene SGCB and colorectal carcinoma.